Skip to content
Review Open access

GLP-1 Receptor Agonists as Multisystem Therapeutics: Mechanistic Basis, Translational Evidence, and Emerging Clinical Applications Beyond Metabolic Disease

Oct 2026 · Journal of Pharmacology, Genetics and Molecular Biology · pp. 29-55 · 0 citations · 112 references

TL;DR

Overall, GLP-1-based therapies represent a promising platform for addressing interconnected metabolic and non-metabolic diseases, however, the strength of evidence varies substantially across indications, highlighting the need for well-designed clinical trials, long-term safety evaluation, and clearer identification of patients most likely to benefit from these therapies.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained popularity as important therapeutic agents extending beyond glycaemic control and weight management. Growing evidence suggests their potential benefits across multiple organ systems through metabolic regulation, intracellular signalling, anti-inflammatory activity, and effects on cellular energy homeostasis. This review examines the molecular basis of GLP-1 receptor signalling, including cAMP–PKA–EPAC, PI3K–AKT, AMPK, and MAPK pathways, and their possible contributions to multisystem protection. Particular emphasis is placed on cardiovascular and renal outcomes, including atherosclerotic cardiovascular disease, obesity-related heart failure with preserved ejection fraction, and chronic kidney disease. Hepatic applications are explored through the effects of GLP-1 RAs on metabolic dysfunction-associated steatosis liver disease and steatohepatitis, with consideration of histological outcomes and emerging multi-incretin therapies. The review further evaluates potential applications in neurological and neuropsychiatric disorders, musculoskeletal and inflammatory conditions, respiratory diseases, sleep-related disorders, and oncology. Evidence from clinical trials is considered alongside preclinical findings to distinguish established therapeutic benefits from emerging hypotheses. Safety considerations, including gastrointestinal and hepatobiliary adverse effects, long-term treatment, discontinuation, affordability, and equitable access, are also discussed. Finally, developments in oral and long-acting formulations, combination therapies, biomarker-guided treatment selection, and artificial intelligence-assisted drug discovery are examined as potential directions for precision incretin pharmacotherapy. Overall, GLP-1-based therapies represent a promising platform for addressing interconnected metabolic and non-metabolic diseases. However, the strength of evidence varies substantially across indications, highlighting the need for well-designed clinical trials, long-term safety evaluation, and clearer identification of patients most likely to benefit from these therapies.

Read PDF

Similar papers

Review Open access Oct 2026

GLP-1 Receptor Biology and the Therapeutic Role of Incretin-Based Agonists in Metabolic Diseases.

Type 2 diabetes (T2DM) and obesity represent a growing global health burden, sharing underlying pathophysiological mechanisms such as impaired insulin signalling and chronic low-grade inflammation. The discovery of the incretin effect opened the way for agonist therapies targeting the glucagon-like peptide-1 receptor (...

Elena Koceva, Gert N. Moll · 0 citations
Review Open access Sep 2026

BEYOND WEIGHT LOSS: EMERGING EXTRA-METABOLIC APPLICATIONS OF GLP-1 RECEPTOR AGONISTS IN CARDIOVASCULAR, RENAL, NEUROLOGICAL AND INFLAMMATORY DISORDERS: A NARRATIVE REVIEW

Introduction. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed as antidiabetic agents exploiting the incretin effect to achieve glucose-dependent insulin secretion. Over the past decade, evidence from large-scale cardiovascular outcome trials (CVOTs), mechanistic studies, and emerging cli...

Paulina Bigda, Zuzanna Rafałowska, Stanisław Rutz et al. · 0 citations
Review Open access Sep 2026

BEYOND GLYCEMIC CONTROL: ORGAN-PROTECTIVE EFFECTS AND SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS – A COMPREHENSIVE REVIEW

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have evolved from glucose-lowering agents for type 2 diabetes (T2D) into multifunctional therapies with effects extending across multiple metabolic and organ systems. This review summarizes current evidence regarding the pleiotropic effects, safety profile, and futur...

M. Bukowska, Katarzyna Otrębska, Dominika Lewandowska et al. · 0 citations
Review Open access Oct 2026

Beyond glycemic control: emerging therapeutic applications of GLP-1 receptor agonists: a comprehensive narrative review

The therapy of type 2 diabetes mellitus and obesity has been changed by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). However, clinical evidences suggest their therapeutic potential extends far beyond glycaemic management with major function in cardiovascular, hepatic, renal and neurological illnesses To give...

Nidhi Srivastava, S. Mehrotra, Shubham Biswas et al. · 0 citations
Review Open access Sep 2026

GLP-1 AND DUAL GLP-1/GIP RECEPTOR AGONISTS AS NEUROPROTECTIVE AGENTS: MECHANISMS, CLINICAL EVIDENCE, AND TRANSLATIONAL PERSPECTIVES

Background: Neurodegenerative diseases are increasingly linked to metabolic dysfunction, such as impaired insulin signaling, mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation. These observations have contributed to the type 3 diabetes hypothesis, which describes AD as a disorder associated with...

B. Tekieli, Wojciech Krzysztof Cyran, Tatsiana Matsiusheuskaya et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.